ArticleSeminars in arthritis and rheumatism2025
Risk and temporal trends of heart failure subtypes in rheumatoid arthritis.
Article in Seminars in arthritis and rheumatism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Natural language processing to enhance rheumatoid arthritis care in clinical studies: a scoping review of applications, data, approaches, challenges and future directions.Rheumatology international · 2026Article
- Heart failure in autoimmune rheumatic diseases.Rheumatology international · 2026Review
- Heart Failure in Rheumatoid Arthritis: Epidemiology, Pathogenesis, Diagnosis, Treatment, and Emerging Insights-A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveEvaluate the risk and temporal trends of heart failure (HF) with preserved (HFpEF) and reduced ejection fraction (HFrEF) in rheumatoid arthritis (RA).
methodsWe performed a retrospective, matched cohort study using Veterans Health Administration (VHA) administrative and health record data from 2000 to 2019. Patients with RA were matched up to 10 non-RA controls on age, sex, and VHA enrollment year. Incident HF and HF-related death were queried, classifying HFpEF and HFrEF using left ventricular EF data from a validated natural language processing tool. HF risk was evaluated using conditional Cox regression, adjusting for demographics, body mass index, smoking, rurality, healthcare utilization, and comorbidity burden. Trends in HF risk were evaluated, stratifying models by RA diagnosis period (2000-2005, 2006-2011, 2012-2017).
resultsWe matched 67,850 patients with RA (mean age 62.5, 87.1 % male) to 570,933 non-RA controls (mean age 61.1, 85.8 % male). HF prevalence increased in both groups over time. Over 5,663,151 person-years of follow-up, 77,440 incident HF diagnoses occurred. RA was associated with an increased risk of HFpEF (aHR 1.51, 95 % CI 1.46-1.57) and HFpEF-related death (2.05, 1.76-2.39), as well as HFrEF (1.34, 1.30-1.38) and HFrEF-related death (1.45, 1.29-1.63). HF risk was accentuated in RA patients with elevated inflammation and seropositive RA. No improvements in HF risk were observed over time (linear p-for-trend >0.05 for all outcomes).
conclusionRA was most strongly associated with HFpEF and HFpEF-related death in this national-level, observational dataset. Heightened risks of HF subtypes have not improved despite advances in RA treatment. Prospective research is needed to support the development ofprevention and management strategies to mitigate HF risk in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.